EGFR and non-small cell lung carcinoma: The detection of mutations in the epidermal growth factor receptor (EGFR) gene has brought encouraging improvements in treatment of advanced NSCLC due to the efficacy of EGFR–tyrosine kinase inhibitors (EGFR‐TKIs) (Fukuoka et al., 2011; Wood et al., 2015).